Amarin Corp Plcuk (AMRN) Interest & Investment Income (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Interest & Investment Income of $2.4 million for Q1 2026, down 15.63% year-over-year from $2.9 million in Q1 2025, and down 5.94% quarter-over-quarter from $2.6 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Interest & Investment Income (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Interest & Investment Income data on file, last reported at $2.4 million in Q1 2026.
- Interest & Investment Income for Q1 2026 came in at $2.4 million, down 15.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.4 million (down 19.31% YoY), and the FY2025 annual result was $10.9 million, down 19.03% from the prior year.
- Interest & Investment Income eased to $2.4 million in Q1 2026 per AMRN's latest filing, from $2.6 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $3.4 million in Q4 2023 and troughed at $203000.0 in Q1 2022.
- A 5-year average of $2.4 million and a median of $2.8 million in 2025 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2023: Interest & Investment Income plunged 56.9% in 2022, then soared 994.09% in 2023.
- A 5-year view of Interest & Investment Income shows it stood at $1.6 million in 2022, then jumped by 117.05% to $3.4 million in 2023, then retreated by 1.46% to $3.4 million in 2024, then dropped by 23.67% to $2.6 million in 2025, then declined by 5.94% to $2.4 million in 2026.
- Business Quant data shows AMRN's Interest & Investment Income at $2.4 million in Q1 2026, $2.6 million in Q4 2025, and $2.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 29.66 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 229.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -645.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 2.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.42 Mn |
| Dec 31, 2025 | 2.58 Mn |
| Sep 30, 2025 | 2.78 Mn |
| Jun 30, 2025 | 2.62 Mn |
| Mar 31, 2025 | 2.87 Mn |
| Dec 31, 2024 | 3.38 Mn |
| Sep 30, 2024 | 3.37 Mn |
| Jun 30, 2024 | 3.27 Mn |
| Mar 31, 2024 | 3.38 Mn |
| Dec 31, 2023 | 3.43 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 3.00 Mn |
| Mar 31, 2023 | 2.22 Mn |
| Dec 31, 2022 | 1.58 Mn |
| Sep 30, 2022 | 750,000.00 |
| Jun 30, 2022 | 288,000.00 |
| Mar 31, 2022 | 203,000.00 |
| Dec 31, 2021 | 301,000.00 |
| Sep 30, 2021 | 163,000.00 |
| Jun 30, 2021 | 285,000.00 |